Arvinas to Present at the 3rd Annual Targeted Protein Degradation Summit

Arvinas, a clinical-stage biotechnology company (Nasdaq: ARVN), will have its President and CEO, John Houston, Ph.D., present at the 3rd Annual Targeted Protein Degradation Summit on October 14-15, 2020.

Rhea-AI Summary

Arvinas, a clinical-stage biotechnology company (Nasdaq: ARVN), will have its President and CEO, John Houston, Ph.D., present at the 3rd Annual Targeted Protein Degradation Summit on October 14-15, 2020. The session, titled "The Promise of PROTAC® Protein Degraders: What’s Next for Arvinas’ Pipeline & Platform," will showcase advancements in Arvinas' PROTAC® technology and introduce new pipeline programs. The company focuses on developing therapies that degrade disease-causing proteins, with two clinical-stage programs targeting advanced prostate and breast cancers.

Argus Session date unavailable

+4.02% session move Open Argus

Details

News Market Reaction – ARVN

The recorded move for ARVN in the trading session of this news was +4.02%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW HAVEN, Conn., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., President and Chief Executive Officer, will present a keynote plenary session at the 3rd Annual Targeted Protein Degradation Summit being held virtually October 14-15, 2020. The presentation will reflect on Arvinas’ advances in its PROTAC® platform and introduce new pipeline programs.

Presentation Details:

Title: The Promise of PROTAC® Protein Degraders: What’s Next for Arvinas’ Pipeline & Platform
Date: Wednesday, October 14, 2020
Time: 11:30 a.m. ET

About Arvinas
Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. The company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com.

Contacts for Arvinas

Investors
Will O’Connor, Stern Investor Relations
ir@arvinas.com

Media
Kirsten Owens, Arvinas Communications
kirsten.owens@arvinas.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the date of Arvinas' presentation at the Targeted Protein Degradation Summit?

Arvinas' presentation is scheduled for October 14, 2020.

Who will present on behalf of Arvinas at the summit?

John Houston, Ph.D., President and CEO of Arvinas, will present.

What is the title of the presentation by Arvinas at the summit?

The presentation is titled "The Promise of PROTAC® Protein Degraders: What’s Next for Arvinas’ Pipeline & Platform."

What technology is Arvinas focused on developing?

Arvinas is focused on developing PROTAC® targeted protein degraders.

What clinical-stage programs does Arvinas currently have?

Arvinas has two clinical-stage programs: ARV-110 for metastatic castrate-resistant prostate cancer and ARV-471 for ER+/HER2- breast cancer.